Salubris Medtech

Salubris Medtech is an innovative cardiovascular medical device platform under Shenzhen Salubris Pharmaceuticals Co., Ltd. The company has developed multiple globally and China-first vascular implant and interventional devices through self-research, acquisitions, and product rights introductions in the fields of neurointervention, cardiovascular intervention, peripheral vascular diseases, structural heart diseases, electrophysiology, and hypertension. It provides comprehensive solutions for the diagnosis, prevention, treatment, and rehabilitation of the above-mentioned cardiovascular diseases. Its core products include the Maurora vertebral artery stent in the field of neurointervention, which is the world’s first sirolimus-eluting stent for vertebral artery stenosis. It received NMPA approval at the end of 2020 and achieved remarkable commercial milestones in 2021. In cardiovascular intervention, the sirolimus-coated coronary drug balloon, featuring globally leading drug-coating technology, is currently in the registration clinical trial stage and is expected to be one of the first sirolimus drug balloons to be marketed in China. For structural heart diseases, the LAMax LAAC left atrial appendage occluder is the earliest domestic product and the most widely used worldwide that has conducted randomized controlled trials with Boston Scientific's WATCHMAN™. It has now entered the registration application stage.